[PDF][PDF] This version is available at https://strathprints. strath. ac. uk/50923
B Godman, RE Malmström, E Diogene, S Jayathissa… - core.ac.uk
Background: There are potential conflicts between authorities and companies to fund new
premium priced drugs especially where there are effectiveness, safety and/or budget …
premium priced drugs especially where there are effectiveness, safety and/or budget …
[PDF][PDF] Dabigatran-a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs
MJC Nuijten - academia.edu
Background: There are potential conflicts between authorities and companies to fund new
premium priced drugs especially where there are effectiveness, safety and/or budget …
premium priced drugs especially where there are effectiveness, safety and/or budget …
[PDF][PDF] Dabigatran–a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs
H der Österreichischen Sozialversicherungsträger - academia.edu
Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize
the use of new drugs Page 1 ORIGINAL RESEARCH ARTICLE published: xx April 2013 doi …
the use of new drugs Page 1 ORIGINAL RESEARCH ARTICLE published: xx April 2013 doi …
Dabigatran and Warfarin for Stroke Prevention in Atrial Fibrillation: Use, Switching, and Clinical Effects Following New Market Entry in Real-World Patients
JC Lauffenburger - 2014 - digitalcommons.imsa.edu
Patients with atrial fibrillation frequently benefit from anticoagulation to prevent stroke and
systemic embolism. For decades, warfarin was the primary oral anticoagulant option despite …
systemic embolism. For decades, warfarin was the primary oral anticoagulant option despite …